Key Points
- Director Vicki Sato sold 22,000 shares of Vir Biotechnology on May 1 at an average price of $10.05 under a pre-arranged Rule 10b5-1 plan, totaling $221,100 and reducing her stake by 2% to 1,078,391 shares (≈$10.84M).
- Vir shares trade near $10 (opened $10.18) with a 52-week range of $4.16–$11.66 and a $1.64B market cap, and analysts have a consensus Moderate Buy rating with a $20.38 price target.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $10.05, for a total transaction of $221,100.00. Following the sale, the director owned 1,078,391 shares of the company's stock, valued at $10,837,829.55. This trade represents a 2.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vir Biotechnology Stock Performance
Shares of VIR opened at $10.18 on Tuesday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $11.66. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -3.22 and a beta of 1.70. The firm has a 50-day simple moving average of $9.51 and a 200-day simple moving average of $7.47.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The business had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. During the same quarter in the prior year, the firm earned ($0.76) earnings per share. The business's quarterly revenue was up 417.8% compared to the same quarter last year. Equities research analysts forecast that Vir Biotechnology, Inc. will post -1.97 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in shares of Vir Biotechnology during the 2nd quarter worth approximately $35,000. FNY Investment Advisers LLC purchased a new position in shares of Vir Biotechnology during the 3rd quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock worth $41,000 after purchasing an additional 1,390 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company's stock worth $43,000 after purchasing an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
VIR has been the subject of several recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Friday, April 10th. HC Wainwright raised their price objective on shares of Vir Biotechnology from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Raymond James Financial upgraded shares of Vir Biotechnology from an "outperform" rating to a "strong-buy" rating and set a $19.00 price objective for the company in a research report on Tuesday, February 24th. Wall Street Zen upgraded shares of Vir Biotechnology from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Finally, Barclays raised their price objective on shares of Vir Biotechnology from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.38.
Get Our Latest Stock Analysis on VIR
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
